Get the Stockscreener App
1.91
3.52%
0.065
After Hours:
1.90
-0.01
-0.52%
Nkarta Inc stock is traded at $1.91, with a volume of 1.59M.
It is up +3.52% in the last 24 hours and up +9.14% over the past month.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$1.845
Open:
$1.84
24h Volume:
1.59M
Relative Volume:
1.08
Market Cap:
$130.92M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.7958
EPS:
-2.4
Net Cash Flow:
$-114.31M
1W Performance:
+39.42%
1M Performance:
+9.14%
6M Performance:
-54.20%
1Y Performance:
-80.69%
1-Day Range:
$1.80
$1.99
1-Week Range:
$1.52
$2.34
52-Week Range:
$1.31
$10.34
Nkarta Inc Stock (NKTX) Company Profile
Name
Nkarta Inc
Sector
Industry
Phone
(925) 407-1049
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Compare NKTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTX
Nkarta Inc
|
1.91 | 130.92M | 0 | -117.50M | -114.31M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Nkarta Inc Stock (NKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Aug-14-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-22-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Jul-28-22 | Initiated | Needham | Buy |
| Jul-18-22 | Initiated | SVB Leerink | Outperform |
| Mar-11-22 | Initiated | Raymond James | Outperform |
| Mar-08-22 | Initiated | H.C. Wainwright | Buy |
| Jan-06-22 | Initiated | William Blair | Outperform |
| Nov-18-21 | Initiated | SMBC Nikko | Outperform |
| Jul-16-21 | Initiated | Oppenheimer | Outperform |
| Aug-04-20 | Initiated | Cowen | Outperform |
| Aug-04-20 | Initiated | Evercore ISI | Outperform |
| Aug-04-20 | Initiated | Mizuho | Buy |
| Aug-04-20 | Initiated | Stifel | Buy |
View All
Nkarta Inc Stock (NKTX) Latest News
Charles Schwab Investment Management Inc. Cuts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World
Nkarta to Participate in an April Investor Conference - GlobeNewswire
NK Cell Pioneer Nkarta Takes Center Stage at Major Healthcare Conference - Stock Titan
Leerink Partnrs Has Bullish Outlook for Nkarta Q1 Earnings - The AM Reporter
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Nkarta: Grinding Lower, Trying To Find Support (NASDAQ:NKTX) - Seeking Alpha
Nkarta: Betting On The Turnaround (NASDAQ:NKTX) - Seeking Alpha
Leerink Partnrs Has Strong Forecast for Nkarta Q1 Earnings - Defense World
What is HC Wainwright’s Forecast for Nkarta Q1 Earnings? - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Receives $14.86 Average Price Target from Brokerages - Defense World
Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - Defense World
HC Wainwright Reiterates Buy Rating for Nkarta (NASDAQ:NKTX) - Defense World
Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Benzinga
Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy - BioPharma Dive
Stifel cuts Nkarta stock price target to $14, maintains buy rating - Investing.com India
Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News
H.C. Wainwright maintains Buy on Nkarta stock with $18 target - Investing.com
Nkarta lays off 3rd of staff to fund autoimmune CAR NK program - Fierce Biotech
Newly pivoted to autoimmune, Nkarta trims staff by over third - FirstWord Pharma
Nkarta’s Strategic Restructuring and NKX019 Progress Drive Buy Rating - TipRanks
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire
Nkarta Posts Narrower Q4 Loss; Discloses Restructuring Plan - Marketscreener.com
Nkarta Announces Major Restructuring and Leadership Changes - TipRanks
Nkarta Inc To Reduce Workforce By 34%, Impacting 53 PositionsSEC Filing - MarketScreener
Nkarta Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Nkarta's Strategic Reset: 34% Staff Cut Powers 5-Year Cash Runway with $380M War Chest - Stock Titan
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - MSN
Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Nkarta Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Nkarta (NKTX) Projected to Post Earnings on Thursday - Defense World
NKTX stock touches 52-week low at $1.69 amid market challenges - Investing.com
Comparing Tempest Therapeutics (NASDAQ:TPST) & Nkarta (NASDAQ:NKTX) - Defense World
Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely? - Simply Wall St
Nkarta to Participate in March Investor Conferences - The Manila Times
NKTX stock touches 52-week low at $1.96 amid market challenges - Investing.com
Leerink Partnrs Forecasts Nkarta FY2029 Earnings - MarketBeat
Leerink Partnrs Comments on Nkarta FY2024 Earnings - Defense World
Leerink Partnrs Comments on Nkarta FY2029 Earnings - Defense World
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Stock Performance Spotlight: Nkarta Inc (NKTX) Ends the Day at 2.09, Down by -3.69 - The Dwinnex
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Rating of “Buy” by Brokerages - Defense World
A new trading data show Nkarta Inc (NKTX) is showing positive returns. - SETE News
Vasculitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, CytoDyn - The Globe and Mail
Monitoring Nkarta Inc (NKTX) after recent insider movements - Knox Daily
The Potential Rise in the Price of Trane Technologies plc (TT) following insiders activity - Knox Daily
Closing Figures: Nkarta Inc (NKTX)’s Negative Finish at 2.17, Down -7.26 - The Dwinnex
TANG CAPITAL MANAGEMENT LLC Increases Stake in Nkarta Inc - GuruFocus
What Does Nkarta Inc’s (NASDAQ: NKTX) Future Hold? - Stocks Register
Nkarta Inc Stock (NKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):